Business
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung diseaseTopline results on track for second half of calendar year 2026 WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that it has completed enrollment
About this update from Roivant Sciences Ltd.
[{"type":"image","alt":"Pulmovant, Inc.","displaySize":"","headline":null,"caption":"Pulmovant, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/5c95ec62cb928b13aafcaaf1396a38dd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZxCXGBa_9wg7zAAgfIM2Mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5c95ec62cb928b13aafcaaf1396a38dd","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung disease","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline results on track for second half of calendar year 2026","length":62,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":239,"olType":false},{"type":"text","content":"WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that it has completed enrollment in the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients.","length":511,"tagName":"p"},{"type":"text","content":"Mosliciguat is a potential first-in-class, once-daily, inhaled sGC activator with a differentiated mechanism of action designed to deliver targeted pulmonary vasodilation with limited systemic side effects for the treatment of PH-ILD. Pulmovant completed enrollment of the PHocus clinical trial in under 12 months from first patient dosed, an impressive timeline in clinical development of treatments for PH-ILD. Pulmovant remains on track to report PHocus topline data in the second half of calendar year 2026.","length":511,"tagName":"p"},{"type":"text","content":"“Completing enrollment of the PHocus study in less than one year from first patient dosed underscores the strong demand for new therapeutic options for patients suffering from PH-ILD. People living with PH-ILD have limited treatment options as current the...